| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer (NCT04523272) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-08-25 |
| A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets (NCT04481607) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-08-24 |
| A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer (NCT04398940) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-08-11 |
| A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) (NCT04344158) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-08-11 |
| A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor (NCT04412564) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-08-05 |
| A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL) (NCT04398953) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-07-20 |
| A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer (NCT04337879) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-07-20 |
| A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH） (NCT04326348) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-07-17 |
| A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (NCT04273815) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-07-06 |
| A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (NCT06507891) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-07-06 |
| A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer (NCT04355520) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-07-01 |
| A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets (NCT04408079) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-06-25 |
| A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors (NCT04207463) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-06-03 |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) (NCT04405505) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-06-01 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule (NCT04275583) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-05-28 |
| A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) (NCT04325763) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-05-27 |
| A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma (NCT04385550) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-05-20 |
| A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) (NCT04324879) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-05-20 |
| A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer (NCT04203719) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-05-09 |
| Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes (NCT04373967) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-04-29 |
| A Study of TQB3455 Tablets in Subjects With Advanced Malignancies (NCT04340427) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-04-10 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets (NCT04275050) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-04-01 |
| A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC) (NCT04278820) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-03-20 |
| A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor (NCT04291248) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-03-01 |
| A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer (NCT04306926) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-03-01 |
| A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer (NCT04236362) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-02-27 |
| Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State (NCT06768632) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-01-02 |
| Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus (NCT03986073) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-01-01 |
| A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701) (NCT04234607) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-01-01 |
| A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) (NCT04306887) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-11-29 |
| A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B (NCT04180150) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-11-18 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors (NCT04128085) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-11-15 |
| Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers (NCT05800418) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-11-04 |
| Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer (NCT04073550) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-10-31 |
| Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer (NCT04073537) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-10-31 |
| A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies (NCT06550713) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-10-22 |
| Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) (NCT04009317) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-08-13 |
| Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (NCT04056572) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-08-13 |
| A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer (NCT04439890) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-08-08 |
| Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (NCT04002622) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-08-06 |
| Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (NCT03972189) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-07-24 |
| Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma (NCT03996408) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-06-24 |
| Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors (NCT03897283) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-06-20 |
| Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） (NCT03910127) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-06-11 |
| Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma (NCT03991975) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-06-11 |
| Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN） (NCT03855384) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-06-11 |
| Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer (NCT03983928) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-06-03 |
| Human Bioequivalence Test of Liraglutide Injection (NCT05029076) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-05-21 |
| Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients (NCT03974594) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-05-21 |
| A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics (NCT03850873) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-05-20 |
| Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. (NCT04061109) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-05-15 |
| A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) (NCT03855358) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-05-09 |
| Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. (NCT04060836) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-05-08 |
| A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma (NCT03825705) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-04-23 |
| A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma (NCT03800706) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-03-25 |
| Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) (NCT03777085) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-01-10 |
| A Bioequivalence Study of Sunitinib Malate Capsules. (NCT05800106) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-12-04 |
| Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers (NCT03847246) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-12-04 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection (NCT04144855) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-11-27 |
| A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms (NCT04339400) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-11-20 |
| Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants. (NCT03714568) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-11-11 |
| A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC. (NCT04385563) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-11-11 |
| A Bioequivalence Study of Dasatinib Tablet (NCT05640804) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-09-09 |
| Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma (NCT03601975) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-08-27 |
| A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer (NCT06278493) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-08-23 |
| A Study of TQ-B3525 on Tolerance and Pharmacokinetics (NCT03510767) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-06-20 |
| Bioequivalence Study of Empagliflozin Tablet in Healthy Participants. (NCT03771781) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-04-16 |
| Tolerance and Pharmacokinetics of TQB2450 (NCT03460457) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-03-15 |
| Study of Anlotinib in Patients With Primary Malignant Bone Tumors (NCT03527888) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-01-31 |
| A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 (NCT03457844) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-01-30 |
| A New Drug Used for Advanced Cancer (NCT03447145) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-12-26 |
| Tolerance and Pharmacokinetics of TQ-B3233 (NCT03453034) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-11-22 |
| A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics (NCT02944864) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-09-13 |
| A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics (NCT03099330) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-07-19 |
| Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers (NCT05765357) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-07-16 |
| A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics (NCT03019276) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-07-05 |
| A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics (NCT02996838) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-05-11 |
| Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma (NCT03456466) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-05-01 |
| A Phase I Clinical Trial of Bevacizumab Injection (NCT05476341) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-04-06 |
| Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma (NCT03461627) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-04-01 |
| Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) (NCT03059797) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-03-27 |
| A Study of Anlotinib in Patients With Hepatocellular Carcinoma (NCT02809534) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-09-01 |
| Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A (NCT02930317) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-08-01 |
| A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients (NCT02825563) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-06-01 |
| A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) (NCT04925141) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-05-10 |
| A Study of AL2846 on Tolerance and Pharmacokinetics (NCT02779699) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-05-01 |
| A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics (NCT02752516) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-04-27 |
| A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients (NCT02671942) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-03-01 |
| Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) (NCT02649361) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-01-01 |
| Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients (NCT02622932) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-12-02 |
| Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) (NCT02586337) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-07-01 |
| Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) (NCT02586350) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-07-01 |
| Study of Anlotinib in Patients With Gastric Cancer(ALTER0503) (NCT02461407) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-06-01 |
| Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) (NCT02449343) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-05-12 |
| Study of Methylnaltrexone in Opioid-Induced Constipation Patients (NCT02574819) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-04-01 |
| A Study of Sinotecean on Tolerance and Pharmacokinetics (NCT02469883) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-03-01 |
| Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） (NCT02388919) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-02-26 |
| Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) (NCT02332499) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2014-12-01 |
| Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B (NCT02287857) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2014-09-01 |
| Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer (NCT04056754) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2014-07-16 |